|5-氟-1-((2R,4S,5R)-4-羟基-5-(羟甲基)四氢呋喃-2-基)嘧啶-2,4(1H,3H)-二酮|CsnPharm

CAS No.: 50-91-9

2'-脱氧-5-氟尿苷 Catalog No. CSN18715

Synonyms: 5-Fluorouracil 2'-deoxyriboside;Deoxyfluorouridine;FDUR

Floxuridine is an oncology drug that belongs to antimetabolites with an GI50 of 5.1 μM for the inhibition of PEPT1.

规格	价格	促销价格	库存	数量

400-920-2911

sales@csnpharm.cn

tech@csnpharm.cn

加入购物车大规格询价

加入收藏

产品咨询

400-920-2911

sales@csnpharm.cn

tech@csnpharm.cn

纯度 & 质量文件批次:

靶点选择性

生物活性

实验方案

技术信息

生物活性

靶点 Thymidylate Synthase

GI50:5.1μM
描述Floxuridine (5-Fluorouracil 2'-deoxyriboside) is a pyrimidine analog and known as an oncology antimetabolite. Floxuridine (0-25 μM; 4-24 hours) is affectd by inhibitors of PARP and its sensitivity of ovarian cancer cells is enhanced. Co-exposed to FdUrd and the PARP inhibitor markedly increases killing cell numbers when its compare to treatment alone in ovarian cancer cells. Floxuridine (300 μM; 4-24 hours) increases p-Chk1 and p-Chk2 in ovarian cancer cell lines. It may induce DNA damage and activate the ATM and ATR checkpoint signaling pathways. Floxuridine (0-2.5 μM; 24 hours) causes a G1/S-phase arrest and following removal of the FdUrd, the G1/S-phase-arrested cells moved synchronously through S phase and into G2/M^[3]. Floxuridine (FUDR) is an ideal drug for hepatic arterial infusion (HAI) due to its short half life, steep dose response curve, high total body clearance, and high hepatic extraction^[4]. Floxuridine is against Mueller Hinton Broth and Tryptic Soy Broth with MIC values of 0.25 μM and 0.81 μM, respectively. It also reported to be a very potent inhibitor of staphylococcal growth (MIC, 0.025–0.00313 μM)^[5].
细胞研究

Cell Data

Cell Lines	Concentration	Assay Type	Time	Activity Description	Data Sources
786-0 cells	-	Function assay	48 h	Anticancer activity against human 786-0 cells after 48 hrs by sulforhodamine B assay, GI50=0.1 μM	19744858
A2780 cells	-	Cytotoxicity assay	5 days	Cytotoxicity against human A2780 cells after 5 days by MTT assay, IC50=0.026 μM	22738636
A498 cells	-	Function assay	48 h	Anticancer activity against human A498 cells after 48 hrs by sulforhodamine B assay, GI50=1.25893 μM	19744858

更多
临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点
NCT00296322	-	-	Completed	-	-
NCT00296322	Stomach Cancer	Phase 3	Completed	-	Korea, Republic of ... more >> Asan Medical Center Seoul, Korea, Republic of, 138-736 Collapse <<
NCT00296335	Stomach Cancer	Phase 3	Completed	-	Korea, Republic of ... more >> Asan Medical Center Seoul, Korea, Republic of, 138-736 Collapse <<

更多
参考文献

实验方案

计算器摩尔计算器总药量计算器工作液计算器
储存液制备
- 1 mg
- 5 mg
- 10 mg
- 1 mM
- 4.0619 mL
- 20.3093 mL
- 40.6186 mL
- 5 mM
- 0.8124 mL
- 4.0619 mL
- 8.1237 mL
- 10 mM
- 0.4062 mL
- 2.0309 mL
- 4.0619 mL

技术信息

CAS号

50-91-9

储存条件

粉末: Inert atmosphere,2-8°C

液体: -20°C:3-6 月 -80°C:12月

分子式

C9H11FN2O5

运输

蓝冰

分子量

246.19

别名

5-Fluorouracil 2'-deoxyriboside;Deoxyfluorouridine;FDUR;NSC-27640;5-FDU;FdUrd;5-Fluorodeoxyuridine;5-FUDR;NSC 26740;floxuridin;fluorodeoxyuridine;fluorouridine deoxyribose;fluoruridine deoxyribose. FUDF. 5FUDR;FUdR. WR138720;氟尿苷

溶解度

DMSO	48.0 mg/mL (195.0 mM)
Water	47.0 mg/mL (190.9 mM)
Ethanol	10.0 mg/mL (40.6 mM)

动物实验配方

大规格询价

号为必填项

姓名: 邮箱: 手机号:

留言:

提交

Cell Lines	Concentration	Assay Type	Time	Activity Description	Data Sources

786-0 cells	-	Function assay	48 h	Anticancer activity against human 786-0 cells after 48 hrs by sulforhodamine B assay, GI50=0.1 μM	19744858
A2780 cells	-	Cytotoxicity assay	5 days	Cytotoxicity against human A2780 cells after 5 days by MTT assay, IC50=0.026 μM	22738636
A498 cells	-	Function assay	48 h	Anticancer activity against human A498 cells after 48 hrs by sulforhodamine B assay, GI50=1.25893 μM	19744858
A549 cells	-	Function assay	48 h	Anticancer activity against human A549 cells after 48 hrs by sulforhodamine B assay, GI50=0.01259 μM	19744858
A549 cells	-	Cytotoxicity assay	72 h	Cytotoxicity against human A549 cells after 72 hrs by MTT assay, EC50=9.74 μM	19917528
A549 cells	-	Cytotoxicity assay	72 h	Cytotoxicity against human A549 cells assessed as cell viability after 72 hrs by WST-8 assay, IC50=0.047 μM	22248856
A549 cells	-	Cytotoxicity assay	72 h	Cytotoxicity against human A549 cells after 72 hrs by microplate reader method, IC50=0.0124 μM	22847019
ACHN cells	-	Function assay	48 h	Anticancer activity against human ACHN cells after 48 hrs by sulforhodamine B assay, GI50=0.03162 μM	19744858
BALB/3T3 cell	-	Proliferation assay	72 h	Antiproliferative activity against mouse BALB/3T3 cells assessed as growth inhibition after 72 hrs by SRB method, IC50=23.9 μM	25644674
BT549 cells	-	Function assay	48 h	Anticancer activity against human BT549 cells after 48 hrs by sulforhodamine B assay, GI50=1 μM	19744858
Caki1 cells	-	Function assay	48 h	Anticancer activity against human Caki1 cells after 48 hrs by sulforhodamine B assay, GI50=0.03162 μM	19744858
CCRF-CEM	-	Growth inhibition assay	-	In vitro concentration required for 50% inhibition of growth of human leukemia cell line CCRF-CEM with hPAP (0.2 unit/mL), GI50=0.0006 μM	11597404
CCRF-CEM cell	-	Growth inhibition assay	-	Tested in vitro for the inhibition of cell growth of human T lymphoblastoid CCRF-CEM cell line (ATCC CCL 119), IC50=0.5 μM	11909716
CCRFCEM cells	-	Function assay	-	Cytostatic activity against human CCRFCEM cells by MTT assay, IC50=0.29 μM	17804231
CCRF-CEM cells	-	Growth inhibition assay	72 h	Cytostatic activity against human CCRF-CEM cells ATCC CCL 119 assessed as growth reduction after 72 hrs, IC50=0.017 μM	17997319
CCRF-CEM cells	-	Growth inhibition assay	72 h	Cytostatic activity in human CCRF-CEM cells assessed as inhibition of cell growth after 72 hrs, IC50=0.017 μM	18078757
CCRF-CEM cells	-	Function assay	48 h	Anticancer activity against human CCRF-CEM cells after 48 hrs by sulforhodamine B assay, GI50=0.00631 μM	19744858
CEM cells	-	Function assay	72 h	Cytostatic activity against human CEM cells expressing human ENT1 transporter after 72 hrs by cell counting in presence of NBMPR, IC50=0.8 μM	21892829
CEM/0 cells	-	Function assay	72 h	Cytostatic activity against human CEM/0 cells after 72 hrs by cell counting, IC50=0.022 μM	21892829
COLO205 cells	-	Function assay	48 h	Anticancer activity against human COLO205 cells after 48 hrs by sulforhodamine B assay, GI50=2.51189 μM	19744858
Colo-357 cells	100 μM	Function assay	15 mins	Activity at MRP5 in human Colo-357 cells assessed as 5-FdUMP accumulation at 100 uM after 15 mins	20930123
DU145 cells	-	Function assay	48 h	Anticancer activity against human DU145 cells after 48 hrs by sulforhodamine B assay, GI50=0.25119 μM	19744858
EKVX cells	-	Function assay	48 h	Anticancer activity against human EKVX cells after 48 hrs by sulforhodamine B assay, GI50=10 μM	19744858
FM3A cells	-	Function assay	2 days	Cytostatic activity against mouse FM3A cells after 2 days by coulter counting analysis, IC50=0.0094 μM	21330014
HCC2998 cells	-	Function assay	48 h	Anticancer activity against human HCC2998 cells after 48 hrs by sulforhodamine B assay, GI50=1.58489 μM	19744858
HCT116 cells	-	Function assay	48 h	Anticancer activity against human HCT116 cells after 48 hrs by sulforhodamine B assay, GI50=0.001 μM	19744858
HCT15 cells	-	Function assay	48 h	Anticancer activity against human HCT15 cells after 48 hrs by sulforhodamine B assay, GI50=0.12589 μM	19744858
HeLa cells	-	Cytotoxicity assay	72 h	Cytotoxicity against human HeLa cells after 72 hrs by MTT assay, EC50=10.26 μM	19917528
HeLa cells	-	Function assay	-	Cytostatic activity against human HeLa cells in presence of 20 uM thymidine, IC50=8.5 μM	21330014
Hela cells	-	Function assay	72 h	Cytostatic activity against human HeLa cells after 72 hrs by cell counting, IC50=0.05 μM	21892829
HeLa cells	-	Cytotoxicity assay	72 h	Cytotoxicity against human HeLa cells after 72 hrs by SRB assay, IC50=6.5 μM	23867603
HepG2 cells	-	Cytotoxicity assay	72 h	Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay, EC50=18.84 μM	19917528
HFF cells	-	Function assay	72 h	Antiparasitic activity against Toxoplasma gondii ATCC 50839 infected in HFF cells after 72 hrs by beta-galactosidase reporter gene assay, EC50=0.91 μM	17698618
HL60 cells	-	Growth inhibition assay	72 h	Cytostatic activity against human HL60 cells ATCC CCL 240 assessed as growth reduction after 72 hrs, IC50=0.012 μM	17997319
HL60 cells	-	Growth inhibition assay	72 h	Cytostatic activity in human HL60 cells assessed as inhibition of cell growth after 72 hrs, IC50=0.012 μM	18078757
HL60 cells	-	Proliferation assay	72 h	Antiproliferative activity against human HL60 cells assessed as growth inhibition after 72 hrs by MTT assay, IC50=0.24 μM	25644674
HL-60(TB) cells	-	Function assay	48 h	Anticancer activity against human HL-60(TB) cells after 48 hrs by sulforhodamine B assay, GI50=0.19953 μM	19744858
HOP62 cells	-	Function assay	48 h	Anticancer activity against human HOP62 cells after 48 hrs by sulforhodamine B assay, GI50=0.02512 μM	19744858
HOP92 cells	-	Function assay	48 h	Anticancer activity against human HOP92 cells after 48 hrs by sulforhodamine B assay, GI50=0.79433 μM	19744858
Hs 578T cells	-	Function assay	48 h	Anticancer activity against human Hs 578T cells after 48 hrs by sulforhodamine B assay, GI50=3.98107 μM	19744858
HT1080 cells	-	Function assay	-	Cytostatic activity against human HT1080 cells by MTT assay, IC50=0.18 μM	17804231
HT-29 cells	-	Function assay	48 h	Anticancer activity against human HT-29 cells after 48 hrs by sulforhodamine B assay, GI50=1.99526 μM	19744858
human ACHN cells	-	Function assay	-	Anticancer activity against human ACHN cells by SRB assay, GI50=2.1 μM	20732810
human SR cells	-	Function assay	48 h	Anticancer activity against human SR cells after 48 hrs by sulforhodamine B assay, GI50=0.01259 μM	19744858
IGROV1 cells	-	Function assay	48 h	Anticancer activity against human IGROV1 cells after 48 hrs by sulforhodamine B assay, GI50=2.51189 μM	19744858
K562 cells	-	Function assay	48 h	Anticancer activity against human K562 cells after 48 hrs by sulforhodamine B assay, GI50=0.79433 μM	19744858
KB cells	-	Cytotoxicity assay	72 h	Cytotoxicity against human KB cells after 72 hrs by SRB assay, IC50=8.69 μM	23867603
KBALB cell	-	Cytotoxicity assay	-	In vitro cell cytotoxicity against KBALB cell line (transformed fibroblast sarcoma cell line), CC50=6.00E-05 μM	12620076
KBALB-STK cell	-	Cytotoxicity assay	-	In vitro cell cytotoxicity against KBALB-STK cell lines expressed in HSV-1 TK, IC50=8.80E-05 μM	12620076
KM12 cells	-	Function assay	48 h	Anticancer activity against human KM12 cells after 48 hrs by sulforhodamine B assay, GI50=2.51189 μM	19744858
L1210 cells	-	Growth inhibition assay	72 h	Cytostatic activity against mouse L1210 cells ATCC CCL219 assessed as growth reduction after 72 hrs, IC50=0.012 μM	17997319
L1210 cells	-	Growth inhibition assay	72 h	Cytostatic activity in mouse L1210 cells assessed as inhibition of cell growth after 72 hrs, IC50=0.012 μM	18078757
L1210 cells	-	Function assay	15 mins	Inhibition of thymidylate synthase in mouse L1210 cells assessed as inhibition of tritium release from [5-3H]deoxyuridine after preincubation for 15 mins by liquid scintillation counting, IC50=0.0006 μM	21330014
L1210 mouse leukemia cells	-	Growth inhibition assay	24 h	Growth inhibition in L1210 mouse leukemia cells after 24 h treatment, IC50=0.0041 μM	11728193
L1210 mouse leukemia cells	-	Growth inhibition assay	48 h	Growth inhibition in L1210 mouse leukemia cells after 48 hr treatment, IC50=0.00064 μM	11728193
L1210 mouse leukemia cells	-	Function assay	2 h	Thymidylate synthase inhibition in L1210 mouse leukemia cells after 2 hr treatment, IC50=0.0079 μM	11728193
L1210/0 cells	-	Function assay	48 h	Cytostatic activity against mouse L1210/0 cells after 48 hrs by cell counting, IC50=0.0009 μM	21892829
L5178Y cell	-	Growth inhibition assay	-	Comparative inhibition of L5178Y cell growth in vitro (concentration required for 50% inhibition), IC50=0.00076 μM	6779007
L5178Y cells	-	Function assay	-	Inhibitory concentration of compound was calculated on L5178Y cells by [14C]Leu incorporation, IC50=2 μM	8246229
LAC cells	-	Cytotoxicity assay	72 h	Cytotoxicity against human LAC cells after 72 hrs by MTT assay, EC50=32.09 μM	19917528
LLC cells	-	Cytotoxicity assay	24 h	Cytotoxicity against mouse LLC cells after 24 hrs by resazurin assay, IC50=14.2 μM	21536448
LLC cells	-	Cytotoxicity assay	72 h	Cytotoxicity against mouse LLC cells after 72 hrs by resazurin assay, IC50=2 μM	21536448
LM cells	-	Function assay	2 h	Thymidylate synthase inhibition in thymidine kinase deficient LM cells after 2 hr treatment, IC50=5.4 μM	11728193
LMTK cells	-	Cytotoxicity assay	5 days	Cytotoxicity against thymidine kinase-deficient mouse LMTK cells after 5 days by MTT assay, IC50=4.5 μM	22738636
LNCaP cells	-	Cytotoxicity assay	-	Cytotoxic concentration in prostate specific antigen (PSA) producing human LNCaP cells, IC50=0.0692 μM	12161157
LoVo cells	-	Proliferation assay	72 h	Antiproliferative activity against human LoVo cells assessed as growth inhibition after 72 hrs by SRB method, IC50=19.07 μM	25644674
LOXIMVI cells	-	Function assay	48 h	Anticancer activity against human LOXIMVI cells after 48 hrs by sulforhodamine B assay, GI50=0.02512 μM	19744858
M14 cells	-	Function assay	48 h	Anticancer activity against human M14 cells after 48 hrs by sulforhodamine B assay, GI50=0.15849 μM	19744858
MALME-3M cells	-	Function assay	48 h	Anticancer activity against human MALME-3M cells after 48 hrs by sulforhodamine B assay, GI50=7.94328 μM	19744858
MCF7 cells	-	Function assay	48 h	Anticancer activity against human MCF7 cells after 48 hrs by sulforhodamine B assay, GI50=0.00631 μM	19744858
MCF7 cells	-	Cytotoxicity assay	72 h	Cytotoxicity against human MCF7 cells after 72 hrs by SRB assay, IC50=12.19 μM	23867603
MDA-MB-231 cells	-	Function assay	48 h	Anticancer activity against human MDA-MB-231 cells after 48 hrs by sulforhodamine B assay, GI50=3.98107 μM	19744858
MDA-MB-231 cells	-	Cytotoxicity assay	-	Cytotoxicity against human MDA-MB-231 cells overexpressing urokinase plasminogen activator, IC50=0.21 μM	20363130
MDA-MB-231 cells	-	Function assay	-	Anticancer activity against human MDA-MB-231 cells by SRB assay, GI50=0.16 μM	20732810
MDA-MB-435 cells	-	Function assay	48 h	Anticancer activity against human MDA-MB-435 cells after 48 hrs by sulforhodamine B assay, GI50=3.16228 μM	19744858
MDA-N cells	-	Function assay	48 h	Anticancer activity against human MDA-N cells after 48 hrs by sulforhodamine B assay, GI50=1.25893 μM	19744858
MOLT4 cells	-	Function assay	48 h	Anticancer activity against human MOLT4 cells after 48 hrs by sulforhodamine B assay, GI50=0.03981 μM	19744858
NCI/ADR-RES cells	-	Function assay	48 h	Anticancer activity against human NCI/ADR-RES cells after 48 hrs by sulforhodamine B assay, GI50=1.25893 μM	19744858
NCI-H226 cells	-	Function assay	48 h	Anticancer activity against human NCI-H226 cells after 48 hrs by sulforhodamine B assay	19744858
NCI-H23	-	Function assay	48 h	Anticancer activity against human NCI-H23 cells after 48 hrs by sulforhodamine B assay, GI50=10 μM	19744858
NCI-H322	-	Function assay	48 h	Anticancer activity against human NCI-H322M cells after 48 hrs by sulforhodamine B assay, GI50=0.50119 μM	19744858
NCI-H460	-	Function assay	48 h	Anticancer activity against human NCI-H460 cells after 48 hrs by sulforhodamine B assay, GI50=0.50119 μM	19744858
NCI-H522	-	Function assay	48 h	Anticancer activity against human NCI-H522 cells after 48 hrs by sulforhodamine B assay, GI50=0.002 μM	19744858
OVCAR-3 cells	-	Function assay	48 h	Anticancer activity against human OVCAR-3 cells after 48 hrs by sulforhodamine B assay, GI50=2.51189 μM	19744858
OVCAR4 cells	-	Function assay	48 h	Anticancer activity against human OVCAR4 cells after 48 hrs by sulforhodamine B assay, GI50=10 μM	19744858
OVCAR5 cells	-	Function assay	48 h	Anticancer activity against human OVCAR5 cells after 48 hrs by sulforhodamine B assay, GI50=6.30957 Μm	19744858
OVCAR8 cells	-	Function assay	48 h	Anticancer activity against human OVCAR8 cells after 48 hrs by sulforhodamine B assay, GI50=0.12589 μM	19744858
PC3 cells	-	Function assay	48 h	Anticancer activity against human PC3 cells after 48 hrs by sulforhodamine B assay, GI50=0.31623 μM	19744858
PC3 cells	-	Function assay	-	Anticancer activity against human PC3 cells by SRB assay, GI50=4.97 μM	20732810
RAW264.7 cells	-	Cytotoxicity assay	72 h	Cytotoxicity against mouse RAW264.7 cells after 72 hrs by resazurin assay, IC50=30 μM	21536448
RPMI8266 cells	-	Function assay	48 h	Anticancer activity against human RPMI8266 cells after 48 hrs by sulforhodamine B assay, GI50=0.79433 μM	19744858
RXF393 cells	-	Function assay	48 h	Anticancer activity against human RXF393 cells after 48 hrs by sulforhodamine B assay, GI50=3.98107 μM	19744858
SF268 cells	-	Function assay	48 h	Anticancer activity against human SF268 cells after 48 hrs by sulforhodamine B assay, GI50=10 μM	19744858
SF295 cells	-	Function assay	48 h	Anticancer activity against human SF295 cells after 48 hrs by sulforhodamine B assay, GI50=0.01259 μM	19744858
SF539 cells	-	Function assay	48 h	Anticancer activity against human SF539 cells after 48 hrs by sulforhodamine B assay, GI50=0.03981 μM	19744858
SK-MEL-2 cells	-	Function assay	48 h	Anticancer activity against human SK-MEL-2 cells after 48 hrs by sulforhodamine B assay, GI50=10 μM	19744858
SK-MEL-28 cells	-	Function assay	48 h	Anticancer activity against human SK-MEL-28 cells after 48 hrs by sulforhodamine B assay, GI50=1.99526 μM	19744858
SK-MEL-5 cells	-	Function assay	48 h	Anticancer activity against human SK-MEL-5 cells after 48 hrs by sulforhodamine B assay, GI50=0.19953 μM	19744858
SKOV3 cells	-	Function assay	48 h	Anticancer activity against human SKOV3 cells after 48 hrs by sulforhodamine B assay, GI50=1.99526 μM	19744858
SN12C cells	-	Function assay	48 h	Anticancer activity against human SN12C cells after 48 hrs by sulforhodamine B assay, GI50=0.19953 μM	19744858
SNB19 cells	-	Function assay	48 h	Anticancer activity against human SNB19 cells after 48 hrs by sulforhodamine B assay, GI50=1.99526 μM	19744858
SNB75 cells	-	Function assay	48 h	Anticancer activity against human SNB75 cells after 48 hrs by sulforhodamine B assay, GI50=0.19953 μM	19744858
SW620 cells	-	Function assay	48 h	Anticancer activity against human SW620 cells after 48 hrs by sulforhodamine B assay, GI50=6.30957 μM	19744858
SW707 cells	-	Proliferation assay	72 h	Antiproliferative activity against human SW707 cells assessed as growth inhibition after 72 hrs by SRB method, IC50=23.86 μM	25644674
T47D cells	-	Function assay	48 h	Anticancer activity against human T47D cells after 48 hrs by sulforhodamine B assay, GI50=1.25893 μM	19744858
TK10 cells	-	Function assay	48 h	Anticancer activity against human TK10 cells after 48 hrs by sulforhodamine B assay, GI50=5.01187 μM	19744858
TSU cells	-	Cytotoxicity assay	-	Cytotoxic concentration in non prostate specific antigen (PSA) producing human TSU cells, IC50=0.058 μM	12161157
U251 cells	-	Function assay	48 h	Anticancer activity against human U251 cells after 48 hrs by sulforhodamine B assay, GI50=0.12589 μM	19744858
UACC257 cells	-	Function assay	48 h	Anticancer activity against human UACC257 cells after 48 hrs by sulforhodamine B assay, GI50=3.16228 μM	19744858
UACC62 cells	-	Function assay	48 h	Anticancer activity against human UACC62 cells after 48 hrs by sulforhodamine B assay, GI50=0.03981 μM	19744858
UO31 cells	-	Function assay	48 h	Anticancer activity against human UO31 cells after 48 hrs by sulforhodamine B assay, GI50=0.12589 μM	19744858

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点

NCT00296322	-	-	Completed	-	-
NCT00296322	Stomach Cancer	Phase 3	Completed	-	Korea, Republic of ... more >> Asan Medical Center Seoul, Korea, Republic of, 138-736 Collapse <<
NCT00296335	Stomach Cancer	Phase 3	Completed	-	Korea, Republic of ... more >> Asan Medical Center Seoul, Korea, Republic of, 138-736 Collapse <<
NCT00296335	-	-	Completed	-	-
NCT01815359	Appendix Cancer ... more >> Colorectal Cancer Collapse <<	Phase 2	Recruiting	March 2019	United States, Florida ... more >> University of Miami Recruiting Miami, Florida, United States Contact: Floriano Marchetti, MD 305-243-9110 United States, Missouri Washington University School of Medicine Recruiting Saint Louis, Missouri, United States, 63110 Contact: Sean Glasglow, MD 314-747-7222 Principal Investigator: Benjamin Tan, MD United States, New Jersey Memorial Sloan Kettering Basking Ridge Recruiting Basking Ridge, New Jersey, United States, 07920 Contact: Garrett Nash, MD, MPH 212-639-8668 Memorial Sloan Kettering Monmouth Recruiting Middletown, New Jersey, United States, 07748 Contact: Garrett Nash, MD, MPH 212-639-8668 Memorial Sloan Kettering Bergen Recruiting Montvale, New Jersey, United States, 07645 Contact: Garrett Nash, MD,MPH 212-639-8668 United States, New York Memorial Sloan Kettering Commack Recruiting Commack, New York, United States, 11725 Contact: Garrett Nash, MD, MPH 212-639-8668 Memorial Sloan Kettering Westchester Recruiting Harrison, New York, United States, 10604 Contact: Garrett Nash, MD, MPH 212-639-8668 Memorial Sloan Kettering Cancer Center Recruiting New York, New York, United States, 10065 Contact: Garrett Nash, MD, MPH 212-639-8668 Contact: Andrea Cercek, MD 646-888-4189 Principal Investigator: Garrett Nash, MD, MPH Memorial Sloan Kettering Rockville Centre Recruiting Rockville Centre, New York, United States, 11570 Contact: Garrett Nash, MD, MPH 212-639-8668 Collapse <<
NCT01401075	Gastric Cancer	Phase 4	Completed	-	Korea, Republic of ... more >> ASAN Medical Center Seoul, Korea, Republic of, 138-736 Collapse <<
NCT01312857	Metastatic Colorectal Cancer	Phase 2	Recruiting	March 2019	United States, New Jersey ... more >> Memorial Sloan Kettering Basking Ridge Recruiting Basking Ridge, New Jersey, United States, 07920 Contact: Nancy Kemeny, MD 646-888-4180 Memorial Sloan Kettering Monmouth Recruiting Middletown, New Jersey, United States, 07748 Contact: Nancy Kemeny, MD 646-888-4180 United States, New York Memorial Sloan Kettering Commack Recruiting Commack, New York, United States, 11725 Contact: Nancy Kemeny, MD, PhD 646-888-4180 Memorial Sloan Kettering Westchester Recruiting Harrison, New York, United States, 10604 Contact: Nancy Kemeny, MD 646-888-4180 Contact: Michael D'Angelica, MD 212-639-3226 Principal Investigator: Nancy Kemeny, MD Memorial Sloan Kettering Cancer Center Recruiting New York, New York, United States, 10065 Contact: Nancy Kemeny, MD 646-888-4180 Contact: Michael D'Angelica, MD 212-639-3226 Principal Investigator: Nancy Kemeny, MD Memorial Sloan Kettering Rockville Centre Recruiting Rockville Centre, New York, United States, 11570 Contact: Nancy Kemeny, MD 646-888-4180 Collapse <<
NCT03693807	Colorectal Cancer ... more >> Cholangiocarcinoma Collapse <<	Phase 2	Recruiting	September 2020	United States, New Jersey ... more >> Memorial Sloan Kettering Basking Ridge Recruiting Basking Ridge, New Jersey, United States, 07920 Contact: Nancy Kemeny, MD 646-888-4180 Memorial Sloan Kettering Monmouth Recruiting Middletown, New Jersey, United States, 07748 Contact: Nancy Kemeny, MD 646-888-4180 Memorial Sloan Kettering Bergen Recruiting Montvale, New Jersey, United States, 07645 Contact: Nancy Kemeny, MD 646-888-4180 United States, New York Memorial Sloan Kettering Commack Recruiting Commack, New York, United States, 11725 Contact: Nancy Kemeny, MD, PhD 646-888-4180 Memorial Sloan Kettering Westchester Recruiting Harrison, New York, United States, 10604 Contact: Nancy Kemeny, MD 646-888-4180 Principal Investigator: Nancy Kemeny, MD Memorial Sloan Kettering Cancer Center Recruiting New York, New York, United States, 10065 Contact: Nancy Kemeny, MD 646-888-4180 Principal Investigator: Nancy Kemeny, MD Memorial Sloan Kettering Rockville Centre Recruiting Rockville Centre, New York, United States, 11570 Contact: Nancy Kemeny, MD 646-888-4180 Collapse <<
NCT01348412	Colorectal Cancer ... more >> Liver Metastases Collapse <<	Phase 2	Completed	-	France ... more >> Centre Georges François Leclerc Dijon, France, 21000 Collapse <<
NCT00020501	Colorectal Cancer ... more >> Metastatic Cancer Collapse <<	Phase 3	Completed	-	United States, Maryland ... more >> Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support Bethesda, Maryland, United States, 20892-1182 Collapse <<
NCT03069950	Colorectal Adenocarcinoma Meta... more >>static to the Liver Collapse <<	Phase 2	Recruiting	February 2020	United States, New Jersey ... more >> Memorial Sloan Kettering Basking Ridge Recruiting Basking Ridge, New Jersey, United States, 07920 Contact: Andrea Cercek, MD 646-888-4189 Principal Investigator: Andrea Cercek, MD Memorial Sloan Kettering Monmouth Recruiting Middletown, New Jersey, United States, 07748 Contact: Andrea Cercek, MD 646-888-4189 United States, New York Memorial Sloan Kettering Commack Recruiting Commack, New York, United States, 11725 Contact: Andrea Cercek, MD Principal Investigator: Andera Cercek, MD Memoral Sloan Kettering Westchester Recruiting Harrison, New York, United States, 10604 Contact: Andrea Cercek, MD 646-888-4189 Memorial Sloan Kettering Cancer Center Recruiting New York, New York, United States, 10065 Contact: Andrea Cercek, MD 646-888-4189 Contact: Michael D'Angelica, MD 212-639-3226 Principal Investigator: Andrea Cercek, MD Collapse <<
NCT00244348	Colorectal Cancer ... more >> Metastasis Liver Cancer Collapse <<	Phase 1 Phase 2	Withdrawn(Investigator has lef... more >>t institution) Collapse <<	-	United States, Wisconsin ... more >> Medical College of Wisconsin/ Froedtert Hospital Milwaukee, Wisconsin, United States, 53226 Collapse <<
NCT02788201	Urothelial Carcinoma ... more >> Bladder Cancer Urinary Bladder Neoplasms Collapse <<	Phase 2	Recruiting	July 1, 2020	United States, Maryland ... more >> National Institutes of Health Clinical Center Recruiting Bethesda, Maryland, United States, 20892 Contact: For more information at the NIH Clinical Center contact National Cancer Institute Referral Office 888-624-1937 Collapse <<
NCT00408551	Colorectal Cancer ... more >> Metastatic Cancer Collapse <<	Phase 2	Unknown	-	United States, Indiana ... more >> Center for Cancer Care at Goshen General Hospital Recruiting Goshen, Indiana, United States, 46526 Contact: Clinical Trials Office - Center for Cancer Care at Goshen Gene 574-535-2858 Collapse <<
NCT01042691	Unresectable Colorectal Liver ... more >>Metastases Collapse <<	Phase 1	Completed	-	United States, Pennsylvania ... more >> UPMC Presbyterian Pittsburgh, Pennsylvania, United States, 15213 UPMC Cancer Centers, Hillman Cancer Center Pittsburgh, Pennsylvania, United States, 15232 UPMC Shadyside Pittsburgh, Pennsylvania, United States, 15232 Collapse <<
NCT00019760	Recurrent Colon Cancer ... more >> Liver Metastases Stage IV Rectal Cancer Recurrent Rectal Cancer Stage IV Colon Cancer Collapse <<	Phase 2	Completed	-	United States, Maryland ... more >> Surgery Branch Bethesda, Maryland, United States, 20892 Collapse <<
NCT00643877	Colorectal Neoplasms	Phase 3	Unknown	December 2014	China ... more >> Zhongshan Hospital, Fudan University Recruiting Shanghai, China, 200032 Principal Investigator: jianmin xu, MD Collapse <<
NCT00004103	Gastric Cancer	Phase 2	Completed	-	United States, New York ... more >> NYU Cancer Institute at New York University Medical Center New York, New York, United States, 10016 Collapse <<
NCT02529774	Resected Liver Metastases From... more >> Colorectal Cancer Collapse <<	Phase 2 Phase 3	Not yet recruiting	September 2021	China, Shanghai ... more >> Fudan University Shanghai Cancer Center China Not yet recruiting Shanghai, Shanghai, China, 200032 Contact: Ye Xu, Dr. +86 21 64175590 xu_shirley021@163.com Contact: Hongtu Zheng, Dr. +86 180 1731 7711 zht5863@126.com Collapse <<
NCT00008294	Colorectal Cancer ... more >> Metastatic Cancer Collapse <<	Phase 1	Completed	-	United States, New York ... more >> Memorial Sloan-Kettering Cancer Center New York, New York, United States, 10021 Collapse <<
NCT03678428	Metastatic Colorectal Cancer ... more >> Liver Metastases Collapse <<	Phase 3	Not yet recruiting	December 31, 2022	China, Guangdong ... more >> Sun Yat-sen University Cancer Center Guangzhou, Guangdong, China, 510060 Collapse <<
NCT02402972	Colorectal Cancer ... more >> Metastasis Collapse <<	Phase 3	Recruiting	February 2022	China ... more >> Zhongshan Hospital, Fudan University Recruiting Shanghai, China, 200032 Contact: Wenju Chang, MD 86-21-13764476150 Principal Investigator: jianmin xu, MD Collapse <<
NCT00448682	Gastric Cancer	Phase 2	Terminated	-	United States, Florida ... more >> University of Miami Sylvester Comprehensive Cancer Center - Miami Miami, Florida, United States, 33136 Collapse <<
NCT00006038	Esophageal Cancer ... more >> Gastric Cancer Collapse <<	Phase 2	Completed	-	United States, New York ... more >> Memorial Sloan-Kettering Cancer Center New York, New York, United States, 10021 Collapse <<
NCT00002783	Gastric Cancer	Phase 2	Completed	-	United States, New York ... more >> Memorial Sloan-Kettering Cancer Center New York, New York, United States, 10021 Collapse <<
NCT00448682	-	-	Terminated	-	-
NCT00522509	-	-	Unknown	-	Italy ... more >> Department of Surgery - Liver Unit, Scientific Institute San Raffaele, Milan, Italy, 20132 Collapse <<
NCT00448760	Esophageal Cancer	Phase 2	Completed	-	United States, Florida ... more >> University of Miami Sylvester Comprehensive Cancer Center - Miami Miami, Florida, United States, 33136 Collapse <<
NCT00448760	-	-	Completed	-	-
NCT01525069	Cholangiocarcinoma ... more >> Liver Neoplasms Collapse <<	Phase 1	Recruiting	June 30, 2022	United States, Missouri ... more >> Washington University School of Medicine Recruiting Saint Louis, Missouri, United States, 63110 Contact: William Chapman, M.D. 314-362-7792 chapmanw@wustl.edu Contact: Tracey Guthrie 314-747-4404 guthriet@wustl.edu Sub-Investigator: William Chapman, M.D. Sub-Investigator: M.B. Majella Doyle, M.D. Sub-Investigator: William Hawkins, M.D. Sub-Investigator: Jeffrey Lowell, M.D. Sub-Investigator: Joel Picus, M.D. Sub-Investigator: Steven Strasberg, M.D. Sub-Investigator: Rama Suresh, M.D. Sub-Investigator: Andrea Wang-Gillam, M.D., Ph.D. Sub-Investigator: Kathryn J. Fowler, M.D. Sub-Investigator: Benjamin Tan, M.D. Sub-Investigator: John Kotyk, M.D. Collapse <<
NCT00001449	Neoplasms	Phase 1	Completed	-	United States, Maryland ... more >> National Cancer Institute (NCI) Bethesda, Maryland, United States, 20892 Collapse <<
NCT00059930	Colorectal Cancer ... more >> Metastatic Cancer Collapse <<	Phase 1	Active, not recruiting	June 2019	United States, New Jersey ... more >> Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School New Brunswick, New Jersey, United States, 08903 United States, New York Memorial Sloan Kettering Cancer Center New York, New York, United States, 10065 Collapse <<
NCT00002716	Colorectal Cancer ... more >> Metastatic Cancer Collapse <<	Phase 3	Completed	-	United States, Iowa ... more >> CCOP - Cedar Rapids Oncology Project Cedar Rapids, Iowa, United States, 52403-1206 CCOP - Iowa Oncology Research Association Des Moines, Iowa, United States, 50309-1016 John Stoddard Cancer Center at Iowa Methodist Medical Center Des Moines, Iowa, United States, 50309 Mercy Cancer Center at Mercy Medical Center-Des Moines Des Moines, Iowa, United States, 50314 Iowa Lutheran Hospital Des Moines, Iowa, United States, 50316-2301 United States, Nebraska Midlands Cancer Center at Midlands Community Hospital Papillion, Nebraska, United States, 68128-4157 United States, New Mexico MBCCOP - University of New Mexico HSC Albuquerque, New Mexico, United States, 87131 United States, Ohio MetroHealth Medical Center Cleveland, Ohio, United States, 44109 United States, Pennsylvania Penn State Cancer Institute at Milton S. Hershey Medical Center Hershey, Pennsylvania, United States, 17033-0850 Fox Chase Cancer Center Philadelphia, Pennsylvania, United States, 19111-2497 United States, Wisconsin CCOP - St. Vincent Hospital Cancer Center, Green Bay Green Bay, Wisconsin, United States, 54307-3453 Australia, New South Wales Westmead Hospital Westmead, New South Wales, Australia, 2145 Peru Instituto de Enfermedades Neoplasicas Lima, Peru, 34 Puerto Rico San Juan City Hospital San Juan, Puerto Rico, 00936-7344 Collapse <<
NCT03500874	Colorectal Cancer ... more >> Liver Metastases HAI Collapse <<	Phase 3	Recruiting	December 31, 2024	China, Guangdong ... more >> Sun Yat-sen University Cancer Center Recruiting Guangzhou, Guangdong, China, 510060 Contact: Yuhong Li, MD +86(20)87343135 kyk@sysucc.org.cn Contact: Yuhong Li, MD +86(20)87342490 liyh@sysucc.org.cn Collapse <<
NCT00026234	Adenocarcinoma of the Colon ... more >> Adenocarcinoma of the Rectum Liver Metastases Recurrent Colon Cancer Recurrent Rectal Cancer Stage IV Colon Cancer Stage IV Rectal Cancer Collapse <<	Phase 2	Completed	-	United States, Minnesota ... more >> North Central Cancer Treatment Group Rochester, Minnesota, United States, 55905 Collapse <<
NCT00005049	Colorectal Cancer ... more >> Gastric Cancer Gastrointestinal Carcinoid Tumor Gastrointestinal Stromal Tumor Ovarian Cancer Peritoneal Cavity Cancer Small Intestine Cancer Collapse <<	Phase 2	Completed	-	United States, New York ... more >> NYU School of Medicine's Kaplan Comprehensive Cancer Center New York, New York, United States, 10016 Collapse <<
NCT00183911	Gastric Adenocarcinoma ... more >> Gastric Cancer Collapse <<	Phase 2	Completed	-	United States, California ... more >> U.S.C. / Norris Comprehensive Cancer Center Los Angeles, California, United States, 90033 Collapse <<
NCT03366155	Colorectal Cancer ... more >> Liver Metastases Colorectal Adenocarcinoma Colorectal Cancer With Hepatic Metastases Colorectal Carcinoma Collapse <<	Phase 2	Not yet recruiting	December 30, 2022	United States, Maryland ... more >> National Institutes of Health Clinical Center Not yet recruiting Bethesda, Maryland, United States, 20892 Contact: For more information at the NIH Clinical Center contact National Cancer Institute Referral Office 888-624-1937 Collapse <<
NCT01862315	Intrahepatic Cholangiocarcinom... more >>a Peripheral Cholangiocarcinoma Cholangiolar Carcinoma Cholangiocellular Carcinoma Collapse <<	Phase 2	Recruiting	May 2019	United States, New Jersey ... more >> Memoral Sloan Kettering Cancer Center Recruiting Basking Ridge, New Jersey, United States Contact: William Jarnagin, MD 212-639-7601 Memorial Sloan Kettering Monmouth Recruiting Middletown, New Jersey, United States, 07748 Contact: William R. Jarnagin, MD 212-639-7601 United States, New York Memorial Sloan Kettering Cancer Center @ Suffolk Recruiting Commack, New York, United States, 11725 Contact: William Jarnagin, MD 212-639-7601 Memorial Sloan Kettering Westchester Recruiting Harrison, New York, United States, 10604 Contact: William Jarnagin, MD 212-639-7601 Memorial Sloan Kettering Cancer Center Recruiting New York, New York, United States, 10065 Contact: William R Jarnagin, MD 212-639-7601 Contact: Nancy Kemeny, MD 646-888-4180 Principal Investigator: William R Jarnagin, MD Memorial Sloan Kettering at Mercy Medical Center Recruiting Rockville Centre, New York, United States Contact: William Jarnagin, MD 212-639-7601 Collapse <<
NCT00645710	Liver Metastases ... more >> Recurrent Colon Cancer Recurrent Rectal Cancer Stage IV Colon Cancer Stage IV Rectal Cancer Collapse <<	Phase 1 Phase 2	Completed	-	United States, California ... more >> City of Hope Duarte, California, United States, 91010 Collapse <<
NCT01692704	Cholangiocellular Carcinoma	Phase 1 Phase 2	Completed	-	Switzerland ... more >> University Hospital Zurich, Department of Oncology Zurich, ZH, Switzerland, 8091 Collapse <<
NCT00449163	Colorectal Cancer	Phase 2	Terminated(Study terminated by... more >> University of Miami Institutional Review Board) Collapse <<	-	United States, Florida ... more >> University of Miami Miami, Florida, United States, 33136 Collapse <<
NCT00200200	Hepatic Metastases ... more >> Colon Cancer Rectal Cancer Collapse <<	Phase 2	Active, not recruiting	November 2019	United States, New Jersey ... more >> Memoral Sloan Kettering Cancer Center Basking Ridge, New Jersey, United States United States, New York Memorial Sloan-Kettering Cancer Center @ Suffolk Commack, New York, United States, 11725 Memorial Sloan-Kettering Cancer Center 1275 York Avenue New York, New York, United States, 10021 Memorial Sloan-Kettering Cancer Center at Mercy Medical Center Rockville Centre, New York, United States, 11570 Memoral Sloan Kettering Cancer Center at Phelps Sleepy Hollow, New York, United States, 10591 Collapse <<
NCT00858338	Gastric Cancer ... more >> Stomach Cancer Collapse <<	Phase 2	Completed	-	United States, New York ... more >> Bellevue Hospital New York, New York, United States, 10016 NYU Cancer Center New York, New York, United States, 10016 NYU Tisch Hospital New York, New York, United States, 10016 Collapse <<
NCT00449163	-	-	Terminated(Study terminated by... more >> University of Miami Institutional Review Board) Collapse <<	-	-
NCT00004142	Colorectal Cancer ... more >> Metastatic Cancer Collapse <<	Phase 2	Completed	-	United States, Texas ... more >> University of Texas - MD Anderson Cancer Center Houston, Texas, United States, 77030-4009 Collapse <<
NCT02102789	Metastatic Colorectal Cancer	Phase 3	Recruiting	December 2024	China, Guangdong ... more >> Sun Yat-sen University Cancer Center Recruiting Guangzhou, Guangdong, China, 510060 Contact: Yu-hong Li, MD, Ph D liyh@sysucc.org.cn Principal Investigator: Yu-hong Li, MD, Ph D Collapse <<
NCT00410956	Liver Cancer	Phase 2	Active, not recruiting	July 2019	United States, New York ... more >> New York Weill Cornell Cancer Center at Cornell University New York, New York, United States, 10021 Memorial Sloan-Kettering Cancer Center New York, New York, United States, 10065 Collapse <<
NCT00002842	Colorectal Cancer ... more >> Metastatic Cancer Collapse <<	Phase 2	Completed	-	United States, California ... more >> City of Hope Comprehensive Cancer Center Duarte, California, United States, 91010-3000 Collapse <<
NCT00003753	Colorectal Cancer ... more >> Metastatic Cancer Collapse <<	Phase 2	Completed	-	United States, New York ... more >> Memorial Sloan-Kettering Cancer Center New York, New York, United States, 10021 Collapse <<
NCT03493061	Colo-rectal Cancer ... more >> Liver Metastases Collapse <<	Phase 2	Recruiting	December 30, 2022	China, Guangdong ... more >> Sun Yat-sen University Cancer Center Recruiting Guangzhou, Guangdong, China, 510060 Contact: Li Yuhong, MD 020-87342487 liyh@sysucc.org.cn Principal Investigator: Li Yuhong, MD Collapse <<
NCT00001576	Colorectal Neoplasm ... more >> Liver Neoplasm Neoplasm Metastasis Collapse <<	Phase 1	Completed	-	United States, Maryland ... more >> National Cancer Institute (NCI) Bethesda, Maryland, United States, 20892 Collapse <<
NCT00492999	Colorectal Cancer ... more >> Metastatic Cancer Collapse <<	Phase 2	Active, not recruiting	May 2019	United States, New Jersey ... more >> Memoral Sloan Kettering Cancer Center Basking Ridge, New Jersey, United States United States, New York Memorial Sloan Kettering Cancer Center @ Suffolk Commack, New York, United States, 11725 Memorial Sloan Kettering Cancer Center New York, New York, United States, 10065 Memorial Sloan Kettering at Mercy Medical Center Rockville Centre, New York, United States Memoral Sloan Kettering Cancer Center@Phelps Memorial Hospital Sleepy Hollow, New York, United States Collapse <<
NCT00005860	Cancer	Phase 1	Completed	-	United States, New York ... more >> Memorial Sloan-Kettering Cancer Center New York, New York, United States, 10021 Collapse <<
NCT00002842	-	-	Completed	-	-
NCT00063960	Colorectal Cancer ... more >> Metastatic Cancer Collapse <<	Phase 2	Completed	-	United States, Arkansas ... more >> Arkansas Cancer Research Center at University of Arkansas for Medical Sciences Little Rock, Arkansas, United States, 72205 United States, Kentucky Central Baptist Hospital Lexington, Kentucky, United States, 40503-9985 United States, Massachusetts Massachusetts General Hospital Cancer Center Boston, Massachusetts, United States, 02114 United States, Minnesota University of Minnesota Cancer Center Minneapolis, Minnesota, United States, 55455 United States, New York Roswell Park Cancer Institute Buffalo, New York, United States, 14263-0001 Memorial Sloan-Kettering Cancer Center New York, New York, United States, 10021 United States, North Carolina Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill Chapel Hill, North Carolina, United States, 27599-7213 Comprehensive Cancer Center at Wake Forest University Winston-Salem, North Carolina, United States, 27157-1082 United States, Oklahoma Integris Oncology Services Oklahoma City, Oklahoma, United States, 73112 United States, Rhode Island University Medical Group Providence, Rhode Island, United States, 02908-4735 Collapse <<
NCT00361842	Colorectal Neoplasms	Phase 2	Completed	-	United States, California ... more >> California Cancer Center Greenbrae, California, United States, 94904 United States, District of Columbia Lombardi Comprehensive Cancer Research Institute, Georgetown University Medical Center Washington DC, District of Columbia, United States, 20057 United States, Florida NW Oncology & Hematology Associates Coral Springs, Florida, United States, 33065 Broward Oncology Associates Fort Lauderdale, Florida, United States, 33308 United States, Georgia St. Joseph's/Candler Health System Inc. Savannah, Georgia, United States, 31405 United States, North Carolina Presbyterian Hospital Charlotte,, North Carolina, United States, 28204 United States, Ohio Gabrail Cancer Center Canton, Ohio, United States, 44718 United States, Oklahoma Cancer Care Oklahoma Oklahoma City, Oklahoma, United States Cancer Care Oklahoma Tulsa, Oklahoma, United States United States, South Carolina South Carolina Oncology Association Columbia, South Carolina, United States, 29210 United States, Tennessee Sarah Cannon Research Institute Nashville, Tennessee, United States, 37203 Canada, Alberta Cross Cancer Institute Edmonton, Alberta, Canada, T6G1Z2 Canada, Quebec Sir Mortimer B. Davis Jewish General Hospital Montreal, Quebec, Canada, H3T1E2 Collapse <<
NCT00587067	-	-	Completed	-	-
NCT00587067	Hepatic Cancer	Phase 2	Completed	-	United States, New York ... more >> Memorial Sloan Kettering Cancer Center New York, New York, United States, 10065 Collapse <<
NCT01938729	Intrahepatic Cholangiocarcinom... more >>a Peripheral Cholangiocarcinoma Cholangiolar Carcinoma Cholangiocellular Carcinoma) (ICC) Collapse <<	Phase 1	Active, not recruiting	September 2019	United States, New Jersey ... more >> Memorial Sloan Kettering Cancer Center at Basking Ridge Basking Ridge, New Jersey, United States United States, New York Memorial Sloan Kettering Cancer Center at Commack Commack, New York, United States, 11725 Memorial Sloan Kettering Cancer Center New York, New York, United States, 10065 Memorial Sloan Kettering Cancer Center at Mercy Medical Center Rockville Centre, New York, United States, 11570 Memorial Sloan Kettering Cancer Center Sleepy Hollow Sleepy Hollow, New York, United States, 10591 Collapse <<
NCT00848783	Gastric Cancer ... more >> Gastric Adenocarcinoma Esophageal Cancer Collapse <<	Phase 2	Terminated(Due to slow accrual... more >>) Collapse <<	-	United States, California ... more >> Norris Cancer Center Los Angeles, California, United States, 90033 United States, New York Bellevue Hospital New York, New York, United States, 10016 NYU Cancer Center New York, New York, United States, 10016 Collapse <<
NCT00848783	-	-	Terminated(Due to slow accrual... more >>) Collapse <<	-	-
NCT00268463	Colorectal Cancer ... more >> Metastatic Cancer Collapse <<	Phase 3	Terminated(The study was termi... more >>nated due to low accrual.) Collapse <<	-	-
NCT00695201	Colon Cancer ... more >>Rectal Cancer Collapse <<	Phase 1	Active, not recruiting	August 2019	United States, New York ... more >> Memorial Sloan Kettering Cancer Center New York, New York, United States, 10065 Collapse <<
NCT00268463	-	-	Terminated(The study was termi... more >>nated due to low accrual.) Collapse <<	-	-
NCT01749397	Stage IV Fallopian Tube Cancer... more >> AJCC v6 and v7 Stage IV Ovarian Cancer AJCC v6 and v7 Stage IV Primary Peritoneal Cancer AJCC v7 Collapse <<	Phase 1	Active, not recruiting	-	United States, Arizona ... more >> Mayo Clinic in Arizona Scottsdale, Arizona, United States, 85259 United States, Maryland Johns Hopkins University/Sidney Kimmel Cancer Center Baltimore, Maryland, United States, 21287 United States, Minnesota Mayo Clinic Rochester, Minnesota, United States, 55905 United States, Missouri Siteman Cancer Center at Washington University Saint Louis, Missouri, United States, 63110 Washington University School of Medicine Saint Louis, Missouri, United States, 63110 Collapse <<

2'-脱氧-5-氟尿苷 Catalog No. CSN18715

靶点选择性

请登录您的专属账户

确认信息